
    
      Patients who have received anti-CMV therapy with intravenous ganciclovir for at least 4 weeks
      that resulted in stable retinitis are randomized to receive one of three doses of oral
      ganciclovir or intravenous ganciclovir for 26 weeks of maintenance.
    
  